Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.35
- Piotroski Score 8.00
- Grade Overweight
- Symbol (MRK)
- Company Merck & Co., Inc.
- Price $109.76
- Changes Percentage (-0.38%)
- Change -$0.42
- Day Low $109.39
- Day High $110.30
- Year High $134.63
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
- Last Earnings 07/23/2024
- Ex-Dividend for 5/16 Dividend 09/16/2024
- Dividend Payable 10/07/2024
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $120.00
- High Stock Price Target $294.00
- Low Stock Price Target $80.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.91
- Trailing P/E Ratio 143.59
- Forward P/E Ratio 143.59
- P/E Growth 143.59
- Net Income $365.00 M
Income Statement
Quarterly
Annual
Latest News of MRK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Newmark Group, Inc. (NMRK) Stock Price, News, Quote & History - Yahoo Finance
Camber Development and Wheelock Street Capital have finished Phase I of 44 Middlesex, an advanced manufacturing campus in Bedford, MA. The project delivers 147,000 sq ft of cutting-edge manufacturing ...
By Yahoo! Finance | 1 day ago -
Merck & Co. Inc. (MRK): A Strong Investment as KEYTRUDA Sales Drive Revenue Growth
A list of top major stocks for investment includes Merck & Co. Inc. among others. The economic landscape, rate cuts, currency dynamics, and market indices are factors influencing investment strategies...
By Yahoo! Finance | 5 days ago -
Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth
The article discusses Merck & Co., Inc. in the context of the best healthcare stocks favored by hedge funds. It highlights the growth potential of the healthcare sector amid economic challenges and pr...
By Yahoo! Finance | 5 days ago